Elevance to Myriad: Why Earnings Dates and Legal Risk Outweigh the Sector Tide

Key Highlights

• Elevance reports October 21 and Molina after the close, with medical cost ratios in focus.
• DaVita fell 5.65% without a clear catalyst while the healthcare sector rose.
• QuidelOrtho and Myriad rebounded sharply on restructuring and balance-sheet news.
• Hims & Hers combines international growth with litigation and regulatory risk.

A rising tide does not lift every stock. On Tuesday healthcare moved toward record levels, with the sector's main exchange-traded fund up roughly 2% and a brokerage upgrade of healthcare equipment and services adding to the tone. Yet DaVita (NYSE:DVA) fell 5.65%, and the other stocks in this article moved less on sector flows than on a dated event of their own: Elevance Health (NYSE:ELV), Molina Healthcare (NYSE:MOH), Hims & Hers Health (NYSE:HIMS), QuidelOrtho (NASDAQ:QDEL) and Myriad Genetics (NASDAQ:MYGN).

This article follows the six through one lens. For each company, what event decides the next three weeks, and how much margin for error does the valuation leave? The answers fall into three groups: insurers facing a cost test, services and platforms where the sector rally did not decide the outcome, and diagnostics companies rebuilding their balance sheets.

The Insurers: One Ratio Decides the Quarter

Elevance and Molina face the same question. Insurers earn thin margins, and the medical cost ratio, the share of premiums spent on care, can move earnings by double digits. The two companies report within hours of each other, so Elevance's figures will set the tone for Molina.

Elevance Health

What happened. Shares rose about 2% to $438.94, close to a 52-week high of $440.61, ahead of third-quarter results before the market opens on October 21. Consensus expects earnings per share of about $4.66, down roughly 22% from a year earlier, on revenue near $49.2 billion.

Why it matters. The company has beaten estimates in seven of the last eight quarters, including $7.45 against a $6.21 consensus in the second quarter. The benefit expense ratio is the number to watch: consensus is 91.4%, against 91.3% a year ago. Membership is also in focus, with total medical enrollment expected at 44.26 million against 45.37 million. UnitedHealth Group (NYSE:UNH) raised its 2026 profit view on October 13 as cost pressures eased, which sets a favorable comparison.

The cushion. At 15.42 times forward earnings, Elevance is priced for steadiness rather than growth.

Molina Healthcare

What happened. Shares rose about 4.5% to $219.63 ahead of results after the close on October 21, with a call on October 22. The stock remains about 10% below its July high of $244.89.

Why it matters. Consensus expects earnings per share of about $0.79 on revenue near $10.85 billion, down roughly 5%. The company beat estimates in only three of the last seven quarters, and two of the misses in 2025 were large. The medical care ratio is expected near 93%, against 92.6% a year ago, and membership fell by 108,000 to 4.93 million last quarter. Options markets imply a double-digit move after the report.

The cushion. Thinner than at Elevance. A forward multiple of 26.49 leaves less room for a weak outlook for 2027.

Services and Platforms: When the Tide Does Not Reach the Stock

DaVita and Hims & Hers show the opposite risk. A strong sector is not a company thesis, and neither stock's price on Tuesday followed the sector in a simple way.

DaVita

What happened. Shares fell 5.65% to $176.43 while the sector hit record levels. No company-specific catalyst is evident in the available information. Reimbursement and policy concerns, or rotation into other names, are possible explanations, though none is confirmed. Volume was well above average.

Why it matters. An unexplained fall raises the importance of the next date. Third-quarter results come after the close on October 29, with consensus at about $3.57 per share on revenue near $3.5 billion. DaVita beat estimates in five of the last seven quarters and has reaffirmed 2026 guidance, with an adjusted earnings per share midpoint of $14.65.

The cushion. At 10.89 times forward earnings, within a 52-week range of $101.00 to $247.49, the shares already carry a large risk discount.

Hims & Hers Health

What happened. Shares rose about 5.5% to $29.71 after the company launched in Germany, including weight management and an expanded men's health offering. The move builds on the June deal with Eucalyptus, and management targets at least $600 million of international revenue in 2026.

Why it matters. Growth sits beside regulatory exposure. A class action tied to the July Federal Trade Commission complaint has a lead-plaintiff deadline of November 2, and compounded GLP-1 products remain a focus. The company had more than 2.5 million subscribers at the end of 2025 and reports a loss of $0.64 per share.

The cushion. Little. The forward multiple of 85.67 means much future growth is already assumed. Results are due November 9.

Diagnostics: Two Rebounds Built on Restructuring

QuidelOrtho and Myriad share a theme. Both rose sharply, and both are changing the shape of the business to repair a balance sheet.

QuidelOrtho

What happened. Shares rose about 12.2% to $14.31 after the company set its third-quarter report for November 3, earlier than the roughly November 5 date that data providers had assumed. The rebound follows a fall of about 7% on Friday, and shares remain near the low end of a 52-week range of $9.92 to $35.58.

Why it matters. A federal judge allowed key claims to proceed on September 30 in a securities class action over its Savanna platform and COVID-related revenue statements. Reports also point to talks to sell the point-of-care business to cut about $2.6 billion of net debt, though the company has not confirmed them.

The cushion. A forward multiple of 12.38 and a market value near $982 million reflect that uncertainty.

Myriad Genetics

What happened. Shares rose about 37% to $5.77 after the company agreed to sell its Prenatal Health business to Labcorp Holdings (NYSE:LH) for $210 million in cash plus the value of inventory at closing. The business includes the Prequel, Foresight, SneakPeek and FirstGene tests, used by more than 600,000 patients over the last twelve months.

Why it matters. Unlike QuidelOrtho, the restructuring here is confirmed. Myriad says the sale narrows the portfolio toward the cancer care continuum and should strengthen the balance sheet. Labcorp expects about $160 million of first-year revenue from the business. Closing is expected by early 2027 and needs regulatory clearance.

The cushion. The market value is about $552 million, the company reports a loss of $0.13 per share, and the 52-week range is $2.74 to $8.50.

The Calendar That Ties Them Together

What the Calendar Tests

Every item above is a test of margin for error. The insurers will show whether medical costs are stabilizing, and Elevance goes first. DaVita will show whether an unexplained fall had an operating cause. The diagnostics names will show whether restructuring translates into a stronger balance sheet, and Hims & Hers will show whether international growth can outpace legal costs.

Risks are specific. For insurers, Medicaid policy after the midterm elections and medical cost trends can move margins quickly. For services and diagnostics, legal exposure and debt can outweigh operating progress. A sector rally can also fade if Treasury yields near 5.1% persist or technology shares recover. The useful comparison is not which stock moved most on Tuesday, but which valuation already allows for the risks the calendar is about to test.

This article is for information only and does not constitute investment advice. Figures reflect Tuesday's trading session.